Genus Oncology is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class agents against the MUC1-C oncoprotein for the treatment of patients with refractory cancers.

We have assembled an experienced team that is committed to developing novel therapeutics targeting MUC1-C using different approaches to address a significant unmet medical need.   More...

Clinical Trials

We are currently recruiting patients for a Phase 2 study for patients with AML (acute myeloid leukemia).
​

The Science

The MUC1-C heterodimeric protein is aberrantly overexpressed at high levels in most human carcinomas and certain hematologic malignancies.​

News and Publications

Current news items and a complete list of scientific publications supporting the work at Genus Oncology, LLC.
​